Ventral Tegmental Area

Anatomy

• In the floor of the midbrain, dorsal to the interpeduncular fossa and medial to the substantia nigra; lies on both sides of the midline.
• Most cells (~60%) are dopaminergic; the rest are GABAergic, with a few glutamatergic neurons.
• Projections: nucleus accumbens, amygdala, hippocampus (mesolimbic); PFC and ACC (mesocortical).
• Input: lateral hypothalamus (medial forebrain bundle), PFC glutamate, laterodorsal tegmentum; inhibition via the lateral habenula.

Functions

• Reward prediction error: a phasic dopamine burst when an outcome is better than expected, a dip when it is worse (Schultz).
• Incentive salience (“wanting”): assigning motivational value to stimuli.
• Approach behavior, exploration and curiosity (Panksepp’s SEEKING system).
• Mesocortical branch: dopamine support for working memory and goal-directed planning.

Connections and chemistry

• VTA → nucleus accumbens (mesolimbic)
• VTA → PFC and ACC (mesocortical)
• Lateral hypothalamus → VTA (medial forebrain bundle)
• Glutamate (+), GABA (−), orexin, opioids

Development

Developmental course through childhood and adolescence.

• The density of dopaminergic fibers reaching the PFC increases until adolescence.
• The rise in reward sensitivity in adolescence is linked to the mesolimbic system maturing earlier than prefrontal control.

Clinical

• ADHD: in 53 untreated adults, dopamine transporter and D2/3 receptor levels were lower along the reward pathway (accumbens, midbrain, left caudate); levels in the accumbens and midbrain related to inattention (Volkow et al., 2009). Stimulants raise synaptic dopamine by blocking the dopamine transporter (methylphenidate also the noradrenaline transporter). B
• Depression and anhedonia: hypoactivity of the mesolimbic system.
• Substance use: addictive substances raise mesolimbic dopamine directly or indirectly.
• Psychosis: the dopamine excess is mainly presynaptic. A meta-analysis of 44 PET/SPECT studies (618 patients, 606 controls) found clearly increased striatal dopamine synthesis and release (d ≈ 0.79), very little change in D2/3 receptors and no change in the dopamine transporter (Howes et al., 2012). Clinical counterpart: aberrant salience. A

Treatment

This region from the perspective of medication, psychotherapy and neuromodulation. Letter badges are evidence levels.

• Stimulants (methylphenidate, amphetamine): block dopamine and noradrenaline reuptake; amphetamine also increases release. First line in ADHD. A
• Antipsychotics: D2 receptor blockade; efficacy and side effects (EPS, prolactin) come from the same receptor. A
• Xanomeline-trospium: the first antipsychotic that does not block D2 (an M1/M4 muscarinic agonist; trospium prevents peripheral side effects). It regulates dopamine release indirectly. FDA-approved for adult schizophrenia (September 2024); not yet approved in children and adolescents. A
• Addiction: all addictive substances raise mesolimbic dopamine; treatment approaches that recalibrate reward (contingency management, motivational interviewing) target this system. B

Assessment

Neuropsychological tasks and measures that probe this region's function.

• Monetary Incentive Delay (MID) task
• Probabilistic reward learning and reward prediction error models
• Dopamine release with PET (research)

Lesions and damage

Clinical findings expected with damage or dysfunction.

• Apathy and loss of motivation; in animals, a marked reduction in exploratory behavior.

In the model

How this structure is defined in the 3D model, and the data source.

CIT168 VTA and parabrachial pigmented nucleus (VTA complex; threshold 0.3).

References

Full citations for the card; links go to the paper (DOI) or a PubMed search.

1. Howes OD et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry 2012;69(8). Search PubMed
2. Volkow ND et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009;302(10):1084–1091. Search PubMed
3. FDA, Cobenfy (ksanomelin and trospiyum klorür), erişkin şizofreni, Eylül 2024. Search PubMed